Dosing of basic pharmacotherapy and its effect on the prognosis of patients hospitalized for heart failure

Česká verzia

Authors: Tomáš Krynský ¹; Otto Mayer Jr. ^1,2; Jan Bruthans ³; Simona Bílková ¹; Josef Jirák ⁴
Authors place of work: II. interní klinika, Lékařská fakulta v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň ¹; Biomedicínské centrum, Univerzita Karlova, Lékařská fakulta a Fakultní nemocnice, Plzeň ²; Centrum kardiovaskulární prevence, Thomayerova nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha ³; Správa informačního systému, Fakultní nemocnice, Plzeň ⁴
Published in the journal: Vnitř Lék 2023; 69(2): 109-118
Category: Original Contributions
doi: https://doi.org/10.36290/vnl.2023.018

Summary

Background: We analyzed the prescription and dosage of essential pharmacotherapy in chronic heart failure (HF) at the time of discharge from the hospitalization for cardiac decompensation and how it may have influenced the prognosis of the patients.

Methods: We followed 4097 patients [mean age 70.7, 60.2% males] hospitalized for HF between 2010 and 2020. The vital status we ascertained from the population registry, other circumstances from the hospital information system.

Results: The prescription of beta-blockers (BB) was 77.5% (or only 60.8% of BB with evidence in HF), 79% of renin-angiotensin system (RAS) blockers, and 45.3% of mineralocorticoid receptor antagonists (MRA). Almost 87% of patients were treated with furosemide at the time of discharge, while only ≈53% of patients with ischemic etiology of HF took a statin. The highest target dose of BB was recommended in ≈11% of patients, RAS blockers in ≈ 24%, and MRA in ≈ 12% of patients. In patients with concomitant renal insufficiency, the prescription of BB and MRA was generally less frequent and on a significantly lower dosage. In contrast, the opposite was true for the RAS blocker (however statistically insignificant). In patients with EF ≤ 40%, the prescription of BB and RAS blockers were more frequent but in a significantly lower dosage. On the contrary, MRAs were recommended in these patients more often and in higher doses. In terms of mortality risk, patients treated only with a reduced dose of RAS blockers showed a 77% higher risk of death within one year (or 42% within five years). A significant relationship was also found between mortality and the recommended dose of furosemide.

Conclusions: The prescription and dosage of essential pharmacotherapy are far from optimal, and in the case of RAS blockers, this affected the patient‘s prognosis as well.

Keywords:

mortality – therapy – chronic heart failure – dose – cardiac decompensation

Zdroje

1. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association, Eur J Heart Fail. 2021;23:352-380.

2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J. 2021;42:3599-3726.

3. Mayer O, Bruthans J, Bilkova S, et al. The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022;166:312-321.

4. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate, Ann Intern Med. 2009;150:604-612.

5. Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long‑Term Registry, Eur J Heart Fail. 2013;15:1173-1184.

6. Bavishi C, Chatterjee S, Ather S, et al. Beta‑blockers in heart failure with preserved ejection fraction: a meta‑analysis, Heart Fail Rev. 2015;20:193-201.

7. Chatterjee S, Biondi‑Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta‑analysis, Bmj. 2013;346:f55.

8. Poole‑Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial, Lancet. 2003;362:7-13.

9. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT‑HF), Lancet, 1999;353:2001-2007.

10. Špinarová M, Špinar J, Pařenica J, et al. Prescription and dosage of RAAS inhibitors in patients with chronic heart failure in the FAR NHL registry, Vnitr Lek. 2019;65:13-14.

11. McMurray JJ, Packer M, Desai AS, et al. Angiotensin‑neprilysin inhibition versus enalapril in heart failure, N Engl J Med. 2014;371:993-1004.

12. Khan MS, Fonarow GC, Ahmed A, et al. Dose of Angiotensin‑Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta‑Analysis, Circ Heart Fail. 2017;10.

13. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med. 1999;341:709-717.

14. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med. 2003;348:1309-1321.

15. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial, Circulation. 2015;131:34-42.

16. Juurlink DN, Mamdani, MM Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study, N Engl J Med. 2004;351:543-551.

17. Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double‑blind, placebo‑controlled trial, Lancet. 2019;394:1540-1550.